Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety

PURPOSE: Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Yujia, Yuan, Dai, Ge, Xueling, Hu, Shunfeng, Li, Peipei, Fang, Xiaosheng, Li, Ying, Zhou, Xiangxiang, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030239/
https://www.ncbi.nlm.nih.gov/pubmed/33842312
http://dx.doi.org/10.3389/fonc.2021.597453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030239/
https://www.ncbi.nlm.nih.gov/pubmed/33842312
http://dx.doi.org/10.3389/fonc.2021.597453

Ejemplares similares